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How liver adjusts and stabilizes its size is unsolved so far; the answers to this question may also provide
insights into mechanisms of hepatocarcinogenesis. Two recent papers suggest a role for Merlin/Nf2 in
control of liver cell turnover, but results appear conflicting at first glance.Maintenance of organ size through physi-
ological cell turnover and rapid restoration
of original weight and cellularity after
resection is one of the most enigmatic
abilities of the liver; it does not take
more than 7 days to regain its original
size after partial hepatectomy. Under-
standing the underlying mechanisms and
their dysregulation is likely to provide
key concepts for molecular liver carcino-
genesis. While the essential role of growth
factor-induced signaling in hepatocellular
proliferation and hepatocarcinogenesis is
well established (Breuhahn et al., 2006),
the mechanism of liver size adjustment
and cellularity (‘‘hepatostat’’) has es-
caped detection. Previous data demon-
strated that the evolutionarily conserved
Hippo kinasepathway represents apotent
regulator of organ size inDrosophila (Hpo/
Wts/Yki) and mammals (Mst/Lats/YAP).
Depending on cell density, its activation
reduces cell proliferation and survival
due to phosphorylation and cytoplasmic
retention of the transcriptional coregula-
tor Yki/YAP. Its dysregulation leads to
tissue overgrowth and tumorigenesis
in vivo (Dong et al., 2007; Camargo et al.,
2007). Diverse physiological regulators
of this pathway, includingMerlin (Hamara-
toglu et al., 2006), have been identified
in Drosophila; however, the regulatory
network controlling YAP activity in
mammals is far from being understood.
The mammalian Merlin homolog Nf2
(neurofibromin 2) is a tumor suppressor
mutated in neurofibromatosis, a genetic
disorder leading to multiple benign and
finally malignant mesenchymal tumors.
The role of Nf2 in liver homeostasis and
tumorigenesis has recently been ap-
proached by two papers (Benhamouche
et al., 2010; Zhang et al., 2010) using an
identicalmodel:aconditional, liver-specificdeletion of Nf2 (Alb-Cre;Nf2lox2/lox2), which
results in hepatomegaly (liver overgrowth)
and subsequent development of multiple
malignant primary liver tumors, similar to
phenotypes resulting from overexpression
of YAP (Camargo et al., 2007; Dong et al.,
2007) or the loss of Mst1/2 (Lu et al.,
2010; Zhou et al., 2009) or WW45
(a homolog of Drosophila Salvador and
adaptor for the Hippo kinase; Lu et al.,
2010; Lee et al., 2010).
But here the commonalities between
the two studies end. In genetic experi-
ments, Zhang et al. demonstrate
that YAP heterozygosity (which on its
own confers no obvious phenotypic
effect) largely rescues the hepatic Nf2-
deletion phenotype, consistent with the
Drosophila pathway. However, Benha-
mouche et al. use phosphorylation
analyses and drug-based inhibition ex-
periments to show a connection to
EGFR signaling instead. Regarding Hippo
pathway kinase activation and YAP regu-
lation, both groups arrive at opposite
conclusions. There is also discordance
on the observed phenotypes: while Zhang
et al. describe the development of HCCs
and biliary hamartomas, Benhamouche
et al. observe the whole spectrum of
malignant hepatocellular, biliary, and
mixed liver tumors. Finally, Zhang et al.
describe a hepatocellular phenotype
(increased turnover/proliferation of hepa-
tocytes) that is not observed by Benha-
mouche et al.; instead, the latter group
observes extensive proliferation of puta-
tive liver progenitor cells (‘‘oval cells,’’
see below) preceding liver tumor forma-
tion, suggesting tumor development
from this cell population. The differences
are quite significant and require a
close look also from a cell biology point
of view.Developmental Cell 19, SeIn the normal liver after partial hepatec-
tomy, most differentiated hepatocytes
enter one to two rounds of replication;
this is sufficient for hepatocellular regen-
eration with no contribution from any
other cell population. If hepatocyte repli-
cation is blocked (e.g., by drugs), there
is a back-up mechanism of poorer effi-
ciency based on proliferation of small
round cells that although biased to biliary
differentiation, seem to have some hepa-
tocytic differentiation potential. Carcino-
gens induce morphologically similar
‘‘oval cells’’ (not necessarily the same
cells) that have been extracted, propa-
gated, and immunologically character-
ized. In rodents, oval cells may give rise
to tumors of hepatocellular, cholangiocel-
lular, and mixed differentiation.
Both manuscripts demonstrate en-
largement of the liver, due partly to exten-
sive ductal proliferation. These lesions are
progressive and take over the majority of
liver tissue. Thus, calling them hamarto-
mas (localized, stable, nonneoplastic
malformations) is not correct, but frankly,
calling them oval cells, implying a bipotent
precursor with both hepatocytic and
cholangiocytic potential, may also miss
the mark. These ductal proliferations
appear to be well delineated toward the
parenchyma and confined to expanding
portal tracts/septa and do not show a
diffuse intercalating migratory phenotype
frequently observed in rodent models
with oval cell proliferation. Neither paper
provides evidence that these ducts give
rise to hepatocellular progeny, and as
differentiated ducts with lumen, they
seem committed to biliary differentiation.
Varying differentiation of resulting tumors
does not prove origin from a bipotent
precursor cell, since secondary tumor
cell plasticity (i.e., relaxation of a strictptember 14, 2010 ª2010 Elsevier Inc. 363
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Previewsdifferentiation pattern) is a common
phenomenon in tumors potentially related
to acquired epigenetic changes.
How may the perceived differences in
signaling be explained? It is important to
note that the major premalignant pheno-
type appears to reside in a biliary cell
type, while the primary target cell popula-
tion both groups have aimed for with their
Alb-Cre construct (hepatoblasts/hepato-
cytes) shows less, if any, phenotype.
Conversely, YAP is required for biliary
development (Zhang et al., 2010). These
considerations leave room for alternative
explanations: Nf2 deficiency may initially
contribute to biliary differentiation of an
albumin-expressing cell population (e.g.,
a subpopulation of hepatoblasts) via YAP,
thus explaining the sensitivity of the Nf2
mutant phenotype to YAP levels. Once
these cells have attained biliary differenti-
ation, the Nf2/YAP dependency is termi-
nated and Nf2/EGFR addiction is
induced. EGFR signaling becomes re-
sponsible for continuous proliferation,
rendering these cells susceptible to
EGFR blockade. Alternatively, YAP may
serve in this context not as an Nf2 effector
but as a modulator of downstream (e.g.,
EGFR) signaling; such crosstalk would
not be unprecedented, but would con-
trast with some cell culture experiments
of Zhang et al. and the current under-
standing of Merlin signaling in Drosophila.
What is the take-homemessage: (1) Nf2
deficiency leads to multiple malignant364 Developmental Cell 19, September 14, 20liver tumors via a persistently proliferating
yet rather differentiated ductal cell popu-
lation that seems to have premalignant
properties, and 2) there is evidence that
in certain cell types and under certain
conditions, YAP aswell as EGFR signaling
are relevant effectors of Nf2.
Important questionsare so far unsolved:
which liver cell populations are autono-
mously affected by YAP- andNf2-deletion
effects, and is there a primary hepatocel-
lularphenotypeand thusa truehepatocyte
function of Nf2? What are the relevant
Nf2-induceddownstreameffectormecha-
nisms in the different liver cell types?Does
the proliferating ductal cell population
have any hepatocellular differentiation
potential in vitro and in vivo, as required
for a bipotent progenitor, or does it show
a largely biliary phenotype? Answers will
largely depend on an unbiased andmetic-
ulous definition of the relevant liver cell
types and their resulting alterations.
Are these findings relevant to the
human situation? So far, this is unclear;
there is no defined human disease coun-
terpart to autonomous ductal prolifera-
tion. Moreover, Nf2 patients are not prone
to liver cancer despite living long enough
to experience it; preliminary screens
have failed to detect Nf2 mutations in
hepatocellular carcinomas (Kanai et al.,
1995). Irrespective of the direct applica-
bility of these tumor phenotypes to the
human condition, these papers clearly
highlight the complexity and cell type-10 ª2010 Elsevier Inc.specificity of tumor suppressor effects
on downstream signaling and point the
way toward further study of this important
issue.
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